Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a report published on Friday morning. The brokerage issued a hold rating on the medical research company's stock.

Other analysts have also issued research reports about the company. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a report on Tuesday, April 1st. HC Wainwright reiterated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a research report on Thursday, April 3rd. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Cytosorbents has a consensus rating of "Moderate Buy" and an average price target of $4.67.

Cytosorbents Price Performance

Shares of Cytosorbents stock traded up $0.04 during trading on Friday, hitting $1.03. 66,687 shares of the stock traded hands, compared to its average volume of 143,870. The firm's fifty day moving average is $1.06 and its 200-day moving average is $1.02. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The stock has a market cap of $64.38 million, a price-to-earnings ratio of -2.86 and a beta of 1.17.

Remove Ads

Cytosorbents (NASDAQ:CTSO - Get Free Report) last announced its quarterly earnings results on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.04. The company had revenue of $9.20 million for the quarter, compared to analysts' expectations of $10.09 million. Cytosorbents had a negative net margin of 49.47% and a negative return on equity of 118.54%. Research analysts expect that Cytosorbents will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after acquiring an additional 32,415 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Cytosorbents during the 4th quarter valued at approximately $99,000. Skylands Capital LLC increased its stake in shares of Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after purchasing an additional 26,195 shares in the last quarter. Millennium Management LLC purchased a new position in shares of Cytosorbents in the fourth quarter valued at approximately $30,000. Finally, Key Client Fiduciary Advisors LLC increased its position in shares of Cytosorbents by 127.0% during the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after purchasing an additional 43,900 shares in the last quarter. Hedge funds and other institutional investors own 32.87% of the company's stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.